NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its quarterly earnings data on Tuesday, February, 25th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.08. View Iovance Biotherapeutics' Earnings History.

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Iovance Biotherapeutics.

13 Wall Street analysts have issued 12-month price targets for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $40.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $33.75 in the next twelve months. This suggests a possible upside of 2.6% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

Headlines about IOVA stock have been trending very negative on Saturday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Iovance Biotherapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Iovance Biotherapeutics.

Some companies that are related to Iovance Biotherapeutics include NOVOZYMES A/S/S (NVZMY), Moderna (MRNA), Neurocrine Biosciences (NBIX), BioNTech (BNTX), Qiagen (QGEN), BIO-TECHNE (TECH), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Spark Therapeutics (ONCE), Ablynx (ABLYF), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Heron Therapeutics (HRTX), Novavax (NVAX) and Bristol-Myers Squibb (BMY).

Iovance Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.46%), Perceptive Advisors LLC (7.46%), Farallon Capital Management LLC (4.95%), Franklin Resources Inc. (4.34%), State Street Corp (3.43%) and Bank of America Corp DE (2.52%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

IOVA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Franklin Resources Inc., Broadfin Capital LLC, State Street Corp, Rafferty Asset Management LLC, Peregrine Capital Management LLC and Credit Suisse AG. View Insider Buying and Selling for Iovance Biotherapeutics.

IOVA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Fairmount Funds Management LLC, Artisan Partners Limited Partnership, Eagle Asset Management Inc., Rothschild & Co. Asset Management US Inc., Crawford Lake Capital Management LLC, Farallon Capital Management LLC and EcoR1 Capital LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOVA stock can currently be purchased for approximately $32.91.

Iovance Biotherapeutics has a market capitalization of $4.16 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]